(SCYX) SCYNEXIS, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(SCYX) SCYNEXIS, Inc. Complete Analysis Pack
SCYNEXIS Business Model Canvas: Strategy in One View
Unlock the full strategic blueprint behind SCYNEXIS, Inc.'s business model. This concise Business Model Canvas shows how the company creates value, manages partnerships, and positions itself in the biotech market. If you want deeper insight for research, investing, or strategy, the full downloadable version is a smart next step.
Partnerships
Merck Sharp & Dohme Corp. research collaboration
SCYNEXIS’ research collaboration with Merck Sharp & Dohme Corp. gives its antifungal work access to Merck’s scale and R&D depth; Merck & Co. reported $64.2 billion in 2024 sales and $17.9 billion in R&D spend. That kind of partner can validate science faster and lift downstream value if discovery hits.
Hansoh Shanghai licensing partnership
SCYNEXIS, Inc. partners with Hansoh Shanghai on ibrexafungerp to support development and commercialization in selected markets, extending reach beyond the U.S. The deal gives SCYNEXIS a local China partner with a large sales base and a foothold in a market where fungal infection demand is growing.
Jiangsu Hansoh Pharmaceutical Group agreement
SCYNEXIS, Inc. lists Jiangsu Hansoh Pharmaceutical Group as a key collaborator, which helps extend regional development and can improve future commercialization reach. Access to local regulatory and commercial channels matters in China, a market with more than 1.4 billion people and one of the world’s largest prescription-drug bases.
R-Pharm, CJSC collaboration
SCYNEXIS, Inc. has a collaboration with R-Pharm, CJSC that extends ibrexafungerp beyond the U.S. and supports local development, registration, and market access. This kind of partner network matters because SCYNEXIS reported no product revenue in 2025 and depends on licensing and collaboration deals to fund its pipeline.
- Expands ibrexafungerp reach outside the U.S.
- Supports registration and local access work.
- Fits SCYNEXIS, Inc. without direct commercial scale.
Clinical research sites and investigators
SCYNEXIS, Inc. depends on clinical research sites and investigators to run Phase 3 and other studies, including the completed CANDLE trial. These partners drive patient enrollment and generate the efficacy and safety data needed for regulatory filings and label expansion.
- Enable Phase 3 execution
- Support patient enrollment
- Produce safety and efficacy data
- Back regulatory submissions
SCYNEXIS Leans on Partners to Fund Growth and Global Expansion
SCYNEXIS, Inc. relies on Merck Sharp & Dohme, Hansoh Shanghai, Jiangsu Hansoh Pharmaceutical Group, R-Pharm, and clinical sites to fund R&D, expand ibrexafungerp, and support registration outside the U.S. In 2025, SCYNEXIS reported no product revenue, so these alliances are central to execution and cash flow.
| Partner | Role | 2025/2026 data |
|---|---|---|
| Merck Sharp & Dohme | Research collaboration | Merck 2024 sales $64.2B; R&D $17.9B |
| Hansoh / Jiangsu Hansoh | China development and commercialization | Extends reach beyond U.S. |
| R-Pharm | Local registration and access | Supports ex-U.S. markets |
What is included in the product
Detailed Word Document
A concise, real-world business model canvas for SCYNEXIS, Inc. mapping its antifungal drug development strategy, partners, customers, and value drivers.
Customizable Excel Spreadsheet
Quickly maps SCYNEXIS, Inc.’s business model to spot pain points and streamline strategy review.
Reference Sources
Provides a credible source trail for SCYNEXIS, Inc., making key claims easier to verify and decisions easier to defend.
Activities
ibrexafungerp development
SCYNEXIS’s core activity is ibrexafungerp development, centered on a first-in-class antifungal that it markets in oral form and advances in intravenous form. As of the latest public filings, the drug has 2 U.S. approved vulvovaginal candidiasis indications and is still being tested across additional fungal uses, making it the company’s main scientific and commercial engine.
BREXAFEMME commercialization
SCYNEXIS, Inc. supports BREXAFEMME, its ibrexafungerp tablet approved by the U.S. FDA in 2021 and expanded in 2022 for recurrent vulvovaginal candidiasis, through product positioning, medical education, and lifecycle management. This approved asset anchors near-term activity as the company builds awareness and supports uptake in a market where the product’s commercial value comes from one branded oral therapy with two labeled uses.
Clinical trials execution
SCYNEXIS runs late-stage clinical trials, with Phase 3 work at the center of its value plan. The CANDLE study completed evaluation of recurrent vulvovaginal candidiasis prevention, and ongoing development is key to expanding the label and opening future indications.
Regulatory and partner management
SCYNEXIS, Inc. centers this activity on filing and defending regulatory packages, steering development plans, and tracking partner duties for its antifungal assets, including one FDA-approved product, BREXAFEMME. In biotech, execution matters because one delay can push reviews, milestones, and launch plans by quarters, not weeks.
It also coordinates with international collaborators and commercialization partners so data, filings, and supply plans stay aligned across markets. The work is value-critical: each regulatory step can affect cash receipts, with partner milestones often tied to approval, label expansion, and launch timing.
- Manages filings and development plans
- Tracks partner obligations and milestones
- Coordinates global and commercial partners
- Supports FDA and market execution
Intellectual property management
SCYNEXIS, Inc. centers its IP work on ibrexafungerp, the company’s only approved drug asset, using patents and related rights to protect exclusivity and raise partnering value. That matters a lot for a single-asset biotech: one protected molecule can support multiple indications, including the U.S. approvals in 2021 and 2022, while patent life and licensing terms shape future cash flow.
- Protects ibrexafungerp exclusivity
- Supports licensing and deal value
- Critical for a single-asset biotech
SCYNEXIS Bets on Ibrexafungerp to Expand Its Single-Asset Franchise
SCYNEXIS, Inc. focuses on ibrexafungerp life-cycle work: BREXAFEMME has 2 U.S. vulvovaginal candidiasis labels, and the company keeps running Phase 3 studies to widen use. It also manages FDA filings, partner work, and patent protection for a single core asset.
| Key activity | Data point |
|---|---|
| Approved U.S. labels | 2 |
| Core asset | Ibrexafungerp |
| Late-stage trials | Phase 3 |
Preview Before You Purchase
Business Model Canvas
The SCYNEXIS, Inc. Business Model Canvas preview you see here is the exact document you’ll receive after purchase. It is not a mockup or sample—this is a live view of the final file, with the same structure, content, and formatting. Once you complete your order, you’ll get full access to this same ready-to-use document.
Resources
ibrexafungerp asset
ibrexafungerp is SCYNEXIS, Inc.'s lead antifungal asset and the core of its Business Model Canvas, because it supports the approved oral tablet and the rest of the pipeline. It is the company’s key resource, with one FDA-approved product and the same molecule used to drive future label-expansion and pipeline value.
BREXAFEMME FDA approval
BREXAFEMME is SCYNEXIS, Inc.'s FDA-approved oral antifungal for vulvovaginal candidiasis, with U.S. approval expanding to recurrent VVC prevention in 2021 and a label for women and girls aged 12 and older. That approved asset gives SCYNEXIS, Inc. a commercial base and, by moving one program from development to market, helps validate its ibrexafungerp platform.
Phase 3 CANDLE data
SCYNEXIS, Inc.'s completed Phase 3 CANDLE dataset is a key clinical asset for recurrent VVC prevention, giving a pivotal 6-month evidence base for ibrexafungerp. The strong trial readout supports regulatory filings, label strategy, and commercial planning because it shows real-world prevention value, not just symptom treatment.
Oral and intravenous formulation capability
SCYNEXIS, Inc.’s key resource is its oral and intravenous ibrexafungerp formulation capability. The oral form already supports outpatient use, while the IV form is aimed at hospital care, broadening the drug’s reach across care settings and making the platform more strategic than a single-route asset.
- Oral plus IV expands use from outpatient to hospital settings.
Fungal disease expertise and partnerships
SCYNEXIS, Inc. relies on deep antifungal R&D expertise, built around its first-in-class ibrexafungerp program, to keep its pipeline focused on hard-to-treat fungal infections. Its partner network adds development and commercialization reach, which helps a small biotech extend capability without building every function in-house.
- Deep antifungal R&D know-how
- Partner-led development support
- Commercial reach beyond the core team
SCYNEXIS Builds Value on BREXAFEMME and Phase 3 CANDLE Data
SCYNEXIS, Inc.’s key resources are its ibrexafungerp platform, 1 FDA-approved product, BREXAFEMME, and the CANDLE Phase 3 dataset for recurrent VVC prevention. The oral and IV formulations widen use across outpatient and hospital care, while the approved asset and clinical data support label expansion and partner value.
| Key resource | Value |
|---|---|
| BREXAFEMME | 1 approved product |
| Platform | Oral + IV ibrexafungerp |
| Clinical asset | Phase 3 CANDLE |
Value Propositions
Approved oral treatment for VVC
BREXAFEMME gives SCYNEXIS, Inc. an FDA-approved oral option for vulvovaginal candidiasis, a condition that affects about 75% of women at least once and recurs in 5% to 8% of cases. Oral dosing can be simpler than more complex therapies, and it supports a branded prescription product in a large, recurring infection market.
Recurrent VVC prevention potential
SCYNEXIS, Inc.'s ibrexafungerp has completed Phase 3 CANDLE for recurrent VVC prevention, extending value beyond acute treatment. Recurrent VVC affects about 138 million women worldwide each year, so a proven prevention option addresses a large unmet need and can support longer-term use beyond single-episode care.
Broad antifungal activity
SCYNEXIS is advancing ibrexafungerp across 3 hard-to-treat settings: invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. That broad antifungal reach expands the drug’s clinical use case beyond one niche and can lift its commercial potential in markets where treatment failure still drives high unmet need.
Oral and IV dosing flexibility
SCYNEXIS is advancing oral and intravenous ibrexafungerp, so the same drug can fit outpatient pills and inpatient infusion care. That matters in severe fungal disease, where treatment often shifts with illness severity; oral ibrexafungerp is already approved in the U.S. for vulvovaginal candidiasis and recurrent VVC, while the IV form is aimed at hospital use.
- Oral use: outpatient convenience
- IV use: inpatient severity control
- One asset, two care settings
Non-azole antifungal option
SCYNEXIS, Inc. offers a non-azole antifungal option with ibrexafungerp (Brenzavvy), the first oral glucan synthase inhibitor approved in the U.S. in 2021. That mechanism helps where azoles can fail or be limited by resistance, making it a niche fit for hard-to-treat fungal infections; the Company reported $0.4 million in revenue in 2024.
- Differentiated non-azole mechanism
- Useful in resistant infections
- Niche value in fungal disease
SCYNEXIS: One Antifungal Asset, Two Big Markets
SCYNEXIS, Inc.'s value proposition is a differentiated non-azole antifungal platform anchored by BREXAFEMME/ibrexafungerp, the first oral glucan synthase inhibitor approved in the U.S. in 2021. It targets recurrent vulvovaginal candidiasis and hard-to-treat invasive fungal infections, giving one asset reach across outpatient and hospital care.
| Key point | Data |
|---|---|
| 2024 revenue | $0.4 million |
| RVC recurrence | 5% to 8% |
| Recurrent VVC global burden | 138 million women |
Customer Relationships
Prescription-based physician relationship
BREXAFEMME is a prescription-only medicine with 2 FDA-approved uses, so SCYNEXIS depends on physician trust to drive adoption. Its core relationships are with OB-GYNs and infectious disease physicians, where clinical education, safety data, and guideline fit matter more than consumer marketing.
Medical affairs engagement
SCYNEXIS, Inc. must use medical affairs to explain clinical evidence and safety data for ibrexafungerp, since specialty antifungals rely on precise, peer-level prescribing. In 2024, the CDC still tracked Candida auris cases in U.S. healthcare settings, so scientific dialogue with healthcare professionals stays core.
That relationship helps turn trial data into trusted use, especially when treatment choices are limited and resistance risk is real.
Partner-led commercialization support
SCYNEXIS, Inc. relies on international partners to handle local commercialization, with relationships built around licensing, development, and execution rather than a large direct sales team. In 2025, this partner-led model kept the Company’s commercial footprint light while letting partners carry market access and launch work abroad.
Clinical investigator collaboration
SCYNEXIS, Inc. keeps close ties with clinical investigators and research centers to drive enrollment, protocol execution, and data readouts for its antifungal pipeline. In its latest filing, the Company reported $0 product revenue and ongoing R&D spending, so these relationships are core to advancing new studies and expanding the pipeline.
- Support faster patient enrollment
- Improve trial quality and data
- Enable pipeline expansion
Regulatory and payer interaction
SCYNEXIS, Inc. must keep active contact with regulators and access teams because BREXAFEMME is its key asset, and FDA labeling, safety language, and payer coverage drive sales. That means every label update and reimbursement step can shape long-term commercial value.
- Regulator dialogue protects labeling.
- Payer access drives market use.
- Safety updates affect adoption fast.
SCYNEXIS Relies on HCP Trust and Regulatory Support Amid Zero Product Revenue
SCYNEXIS, Inc. keeps Customer Relationships centered on HCP trust, regulators, and trial sites for BREXAFEMME and ibrexafungerp. In 2025, the Company still reported $0 product revenue, so medical education, label support, and payer access stayed more important than broad consumer marketing.
| Relationship | 2025 data | Why it matters |
|---|---|---|
| HCPs | $0 product revenue | Drives prescribing |
| Regulators | Label and safety focus | Protects access |
Channels
Retail and specialty pharmacy
BREXAFEMME reaches patients mainly through prescription dispensing at retail and specialty pharmacies, the key access point for an approved oral medicine. For outpatient vulvovaginal candidiasis, this channel matters because it links diagnosis, prescription fill, and treatment start in one step.
Hospital and inpatient formulary access
Hospital and inpatient formulary access is critical for SCYNEXIS, Inc. because potential IV and invasive-disease use runs through hospital channels, where serious fungal infections like candidemia can carry mortality near 40%. In 2025/2026, formulary wins can also support future label expansion into broader inpatient use.
Licensing partner networks
SCYNEXIS uses 3 license partners—Hansoh, Jiangsu Hansoh, and R-Pharm—to enter licensed territories without building local sales teams. These partners add commercial and regulatory reach, so SCYNEXIS can extend beyond direct U.S. coverage while keeping fixed operating costs lower.
Healthcare professional education
SCYNEXIS, Inc. uses medical education and scientific engagement to explain ibrexafungerp to gynecologists and infectious disease specialists, which matters because it is a niche antifungal with a narrow prescriber base. This channel supports awareness and adoption around its 1 approved antifungal asset, so field education can shape diagnosis and treatment choices.
- Targets gynecologists and ID specialists
- Uses medical education and science-led outreach
- Fits a niche antifungal market
Clinical and scientific conferences
Clinical and scientific conferences let SCYNEXIS, Inc. share trial data fast and meet the exact specialists who shape antifungal use. For a science-led biotech, this channel builds credibility when product revenue is still limited and the main asset is evidence.
Show data to key researchers.
Build trust through peer review.
Raise visibility at low cost.
SCYNEXIS Sales Channels: Pharmacies, Hospitals, and Partners Drive Reach
SCYNEXIS, Inc. sells BREXAFEMME mainly through retail and specialty pharmacies, while hospital formulary access matters for invasive antifungal use. It also reaches gynecologists and ID specialists through medical education and conference data.
| Channel | Role | 2025/2026 note |
|---|---|---|
| Specialty/retail pharmacies | Fill outpatient scripts | Core for BREXAFEMME |
| Hospitals | Formulary access | Key for serious infections |
| Partners | Territory reach | 3 license partners |
Customer Segments
Women with vulvovaginal candidiasis
Women with vulvovaginal candidiasis are the core approved patient segment for BREXAFEMME, SCYNEXIS, Inc.'s oral antifungal. VVC is common and usually treated in outpatient care; CDC data show about 75% of women will have at least one episode in their lifetime, creating a large recurring need for convenient oral treatment.
Women with recurrent VVC
Women with recurrent VVC are a higher-need segment, with about 5% to 8% of women affected and roughly 3 million U.S. cases a year. SCYNEXIS, Inc.’s completed CANDLE study was built to prevent recurrence, which supports future label expansion and could drive repeat use if approved.
Patients with invasive fungal infections
SCYNEXIS targets patients with invasive fungal infections, especially invasive candidiasis and invasive aspergillosis, where treatment usually starts in hospitals and specialty centers. These infections can be severe, with invasive candidiasis carrying mortality often above 30%, so success with ibrexafungerp could create high clinical value and support premium hospital use.
Gynecologists and OB-GYN practices
Gynecologists and OB-GYN practices are a core customer segment for SCYNEXIS because they diagnose and treat vulvovaginal candidiasis, which affects about 75% of women at least once and recurs in roughly 5% to 8%. They drive first-line choice and repeat prescribing, so physician uptake directly supports product adoption.
- Key VVC prescribers and diagnosticians
- Shape repeat treatment decisions
- High reach across women’s health care
Infectious disease specialists and hospitals
Infectious disease specialists and hospitals are key customers for SCYNEXIS because they drive treatment of invasive and refractory fungal infections, where IV access and formulary placement matter most. Hospital pharmacy and therapeutics committees also shape use of SCYNEXIS beyond VVC, so this segment can support the broader pipeline and future inpatient demand.
- Drives IV formulary access
- Targets hard-to-treat fungal cases
- Supports pipeline expansion beyond VVC
SCYNEXIS Targets Two High-Value Fungal Infection Markets
SCYNEXIS, Inc. serves two main customer groups: women treated for vulvovaginal candidiasis, including the about 75% who will get at least one episode in life and the 5% to 8% with recurrent VVC, and hospitals or infectious disease teams treating invasive fungal infections. Gynecologists, OB-GYNs, and hospital P&T committees shape uptake and access.
| Segment | Key data |
|---|---|
| VVC patients | 75%, 5%–8% |
| Hospital buyers | Severe IFIs |
Cost Structure
Research and development spending
SCYNEXIS, Inc. is a biotech, so research and development stays its main cost driver: in FY2024, R&D was about $12.7 million, funding discovery, preclinical work, and formulation development for ibrexafungerp. That spend is needed to move ibrexafungerp across indications and support future filings.
Clinical trial costs
Phase 3 work like CANDLE is a major cash drain for SCYNEXIS, Inc.: site fees, patient enrollment, monitoring, and statistical analysis add up fast, and late-stage trials often need dozens of sites and hundreds of patients. In the company’s 2025–2026 period, this cost bucket remained one of the biggest uses of cash in development.
Regulatory and quality costs
In fiscal 2025, SCYNEXIS, Inc. had to keep funding FDA regulatory submissions and quality systems to support Brexafemme and any new indication filings. These costs cover compliance, batch release, and ongoing post-approval oversight, and they are a non-discretionary gate to market access.
That spend stays tied to approved-product maintenance and label expansion work, so cuts can slow filings and delay revenue upside.
Manufacturing and supply chain costs
SCYNEXIS, Inc.’s manufacturing and supply chain costs center on BREXAFEMME tablets and planned IV supply, which need ongoing CMC work, batch testing, and GMP distribution. As a single-product company with one approved drug and one product family to support, reliable supply matters because any delay can hit prescription sales fast.
- CMC spend for tablets and IV supply
- Fixed testing and release costs
- Variable packaging and distribution
- Supply continuity protects revenue
General, administrative, and legal costs
SCYNEXIS, Inc. must keep funding corporate overhead, IP protection, and partnership work, and in a patent-heavy biotech model legal spend can be a major cash use. These general, administrative, and legal costs support the operating base, especially when the company is defending and managing its fungal drug IP.
- Funds overhead and core staff
- Protects patent rights
- Manages partners and contracts
- Legal costs can run high
SCYNEXIS Keeps Spending Heavy on R&D, Trials, and Compliance
SCYNEXIS, Inc.’s cost base is still dominated by R&D, with FY2024 R&D at about $12.7 million, plus Phase 3 trial spend, FDA/CMC work, and quality systems. G&A, IP, and legal costs stay material because a single-asset biotech must keep patents, compliance, and supply ready.
| Cost driver | Latest figure |
|---|---|
| R&D, FY2024 | $12.7 million |
| Clinical trials | Major cash use |
| Regulatory and CMC | Non-discretionary |
| G&A and legal | Material overhead |
Revenue Streams
BREXAFEMME product sales
Approved U.S. sales of BREXAFEMME were SCYNEXIS, Inc.'s only direct product revenue stream, but they were modest and uneven; in 2024, net product sales were $0 after the company shifted away from commercialization. If prescription demand had scaled, this would have been recurring, volume-based revenue from each refill and new script.
License fees from partners
SCYNEXIS can earn upfront license fees from partners, which adds non-product cash and helps fund development. For example, Hansoh paid $5 million upfront for ibrexafungerp rights in Greater China, and R-Pharm expanded reach in Russia and CIS, showing how partner deals can monetize the pipeline beyond direct sales.
Development milestones
SCYNEXIS, Inc. can earn milestone cash from collaboration deals when partners hit clinical, regulatory, or launch targets. This matters in biotech because the GSK license for ibrexafungerp carried up to about $500 million in potential milestone payments, showing how one program can turn progress into non-dilutive revenue.
Royalties on partnered markets
SCYNEXIS, Inc. can earn ex-U.S. royalties if partners commercialize licensed products, so this is a capital-light upside stream that scales with partner sales. In 2025, the key point was still optionality: royalty cash flow depends on partner launch timing and market penetration, not on SCYNEXIS, Inc. spending more capital.
- Ex-U.S. sales drive royalty income.
- Low capex, high margin upside.
- Revenue rises with partner execution.
Research and commercialization collaboration revenue
SCYNEXIS, Inc. uses research and commercialization deals to earn reimbursement for shared development work and supply-related payments, which helps offset the cost of a single-asset biotech model. In FY2025, this kind of revenue remained a small but useful buffer around ibrexafungerp-linked activity, supporting cash flow without relying only on product sales.
- Shared R&D costs lower burn.
- Supply payments add non-dilutive cash.
- Reduces single-asset revenue risk.
SCYNEXIS Revenue Stays Partner-Led, With Royalties Driving Upside
SCYNEXIS, Inc.’s revenue stream in FY2025 was still partner-led: no meaningful direct product sales, and cash came from license fees, milestones, royalties, and cost-sharing. One clean example is Hansoh’s $5 million upfront fee for Greater China rights, while the GSK ibrexafungerp deal carried up to about $500 million in potential milestones.
| Stream | FY2025/2026 lens | Value |
|---|---|---|
| Direct product sales | BREXAFEMME | Nil/immaterial |
| Upfront license fee | Hansoh deal | $5 million |
| Milestones | GSK deal | Up to $500 million |
Royalties and shared development or supply payments stay the key upside because they scale with partner execution, not SCYNEXIS, Inc. capex. That keeps the model capital-light, but also tied to launch timing and market uptake.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.